The FDA has approved Ranexa (ranolazine extended-release tablets, from CV Therapeutics) for the first-line treatment of chronic angina. The labeling has been updated to show that Ranexa reduces ventricular arrhythmias, new-onset atrial fibrillation, and bradycardia in coronary artery disease (CAD). Ranexa also showed small reductions in HbA1c but should not be considered a treatment for diabetes.

Ranexa may be used as monotherapy or in combination with other treatments for chronic angina including beta-blockers, calcium channel blockers, and nitrates.

For more information call (877) CVT-7171 or visit